EGFR T790M mutation is sensitive to osimertinib as a second line therapy.[5] The latter is a tumor cell alteration occurring in proteins other than the targeted oncoprotein, which includes downstream signaling pathways and parallel bypass signaling pathways. This evidence concerns the gene EGFR and neoplasm.